Pancreatic Enzyme Replacement Therapy: Drugs

Department of Health and Social Care written question – answered at on 7 March 2025.

Alert me about debates like this

Photo of Edward Morello Edward Morello Liberal Democrat, West Dorset

To ask the Secretary of State for Health and Social Care, if he will take steps to ensure a continuous supply of pancreatic enzyme replacement therapy medications.

Photo of Edward Morello Edward Morello Liberal Democrat, West Dorset

To ask the Secretary of State for Health and Social Care, what (a) guidance and (b) support his Department has made available to healthcare professionals on the management of patients impacted by pancreatic enzyme replacement therapy medications shortages.

Photo of Edward Morello Edward Morello Liberal Democrat, West Dorset

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of shortages of pancreatic enzyme replacement therapy medications on patients.

Photo of Edward Morello Edward Morello Liberal Democrat, West Dorset

To ask the Secretary of State for Health and Social Care, what discussions his Department has had with pharmaceutical manufacturers on resolving supply chain issues with pancreatic enzyme replacement therapy medications; and what his planned timetable is for the restoration of normal supply levels.

Photo of Karin Smyth Karin Smyth Minister of State (Department of Health and Social Care)

The Department is continuing to engage with all suppliers of pancreatic enzyme replacement therapy (PERT) to boost production to mitigate the supply issue. Through this work we have managed to secure additional volumes of PERT for 2025. The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. In December 2024, the Department issued further management advice to healthcare professionals. This directs clinicians to consider these unlicensed imports when licensed stock is unavailable and includes actions for integrated care boards to ensure local mitigation plans are put in place and implemented. The Department, in collaboration with NHS England, has created a webpage to include the latest update on PERT availability and easily accessible advice on the prescribing and ordering of alternative PERT products.

We expect normal supply to resume in 2026 but will remain focused on pushing manufacturers to shorten this timeline. The Department also has frequent conversations with representatives from the impacted patient groups so that they are informed on the supply situation and the mitigation actions being taken.

Does this answer the above question?

Yes0 people think so

No1 person thinks not

Would you like to ask a question like this yourself? Use our Freedom of Information site.